PDGFR-beta Inhibitors
Santa Cruz Biotechnology now offers a broad range of PDGFR-beta Inhibitors. The biological effects of Platelet-derived growth factor (PDGF) proteins are mediated via two tyrosine kinase receptors, PDGFR-α and PDGFR-β. PDGF-mediated signaling is critical for development of many organ systems and is important for growth and survival. PDGFR-beta Inhibitors offered by Santa Cruz inhibit PDGFR-beta and, in some cases, other development and tyrosine kinase receptor related proteins. View detailed PDGFR-beta Inhibitor specifications, including PDGFR-beta Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 21 to 30 of 44 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SU 4312 | 5812-07-7 | sc-200637 sc-200637A | 5 mg 25 mg | $99.00 $367.00 | 2 | |
SU 4312 (CAS 5812-07-7) effectively inhibits PDGFR-beta, a crucial protein in cellular signaling. By targeting this interaction, it modulates specific pathways, holding relevance in various biological investigations. | ||||||
AGL 2043 | 22617-28-8 | sc-203808 | 1 mg | $295.00 | ||
AGL 2043 (CAS 22617-28-8) functions as an inhibitor of PDGFR-beta, a pivotal protein in cellular signaling. By targeting this interaction, it influences specific pathways, offering potential insights into various biological processes. | ||||||
GTP 14564 | 34823-86-4 | sc-203062 | 10 mg | $129.00 | 3 | |
GTP 14564 (CAS 34823-86-4) effectively inhibits PDGFR-beta, a critical protein in cellular signaling. By targeting this interaction, it modulates specific pathways, offering potential insights into diverse biological processes. | ||||||
Tyrphostin AG 1433 | 168836-03-1 | sc-205984 sc-205984A | 1 mg 5 mg | $48.00 $200.00 | ||
Tyrphostin AG 1433 (CAS 168836-03-1) functions as an inhibitor of PDGFR-beta, a pivotal protein in cellular signaling. By targeting this interaction, it modulates specific pathways, offering potential insights into diverse biological processes. | ||||||
Masitinib | 790299-79-5 | sc-211777 | 10 mg | $184.00 | ||
Masitinib is another experimental PDGFR-Beta inhibitor being studied for its potential in various cancers, including gastrointestinal stromal tumors. | ||||||
Cediranib | 288383-20-0 | sc-483599 sc-483599A sc-483599B | 5 mg 10 mg 25 mg | $137.00 $220.00 $406.00 | ||
Cediranib is a VEGFR and PDGFR inhibitor that has been studied in research models for various cancer types, including ovarian, lung, and colorectal cancers. | ||||||
PDGFR Tyrosine Kinase Inhibitor VI, SU6668 | 210644-62-5 | sc-204175 | 5 mg | $79.00 | 9 | |
PDGFR Tyrosine Kinase Inhibitor VI (SU6668) effectively inhibits PDGFR-beta, a crucial protein in cellular signaling. By targeting this interaction, it modulates specific pathways, offering potential insights into diverse biological processes. | ||||||
PD 166285 | 212391-63-4 | sc-208153 | 5 mg | $146.00 | 2 | |
PD 166285 acts as a selective inhibitor of PDGFR-beta, showcasing a unique binding affinity that disrupts receptor dimerization. Its molecular structure facilitates specific electrostatic interactions and conformational changes, leading to altered signaling pathways. The compound exhibits notable reaction kinetics, with a rapid onset of action and prolonged effects on downstream targets. Additionally, its lipophilic characteristics enhance membrane permeability, optimizing cellular uptake and interaction with PDGFR-beta. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a tyrosine kinase inhibitor targeting VEGFR, EGFR, and PDGFR-β. It has been studied for advanced medullary thyroid cancer. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Ponatinib is a kinase inhibitor that targets PDGFR-Beta among other kinases. | ||||||